Application Serial No.: 10/585,040 Inventor(s): MEYNIAL-SALLES *et al.* Attorney Docket No.: 2912956-029000

AMENDMENTS TO THE CLAIMS

Claim 1. (Currently Amended) A method for the preparation of a strain of evolved

micro-organisms <u>E. coli</u> for the production of 1,2-propanediol by the metabolism of a simple

carbon source, said method comprising:

(a) providing an initial bacterial <u>E. coli</u> strain comprising deletion of *tpiA* gene and

deletion of at least one gene involved in the conversion of methylglyoxal into lactate;

(b) culturing the initial bacterial <u>E. coli</u> strain, under selection pressure in an appropriate

growth medium comprising a simple carbon source for a time period sufficient to allow an

increase in growth;

(c) causing evolution, in said initial <u>E. coli</u> strain, of one or more <u>endogenous</u> genes

involved in the biosynthesis pathway from DHAP to methylglyoxal and then to 1,2-propanediol

towards evolved genes having an improved 1,2-propanediol synthase activity by applying

increasing rates of dilution in such a way as to conserve in the growth medium only those E.coli

strain that display a growth rate equal to or higher than the imposed rate of dilution to provide an

evolved strain; and

(d) selecting and isolating the evolved <u>E. coli</u> strain of micro-organisms having an

improved 1,2-propanediol synthase activity.

Claim 2. (Previously Presented) The method of claim 1, wherein the gene involved in the

conversion of methylglyoxal into lactate is selected from the group consisting of gloA, aldA and

aldB.

Claim 3. (Currently Amended) The method of claim 1, wherein the initial E. coli strain

comprises deletion of genes gloA, aldA, and aldB.

Claim 4. (Currently Amended) The method of claim 1, wherein the initial *E. coli* strain

comprises deletion of genes ldhA, pflA, pflB, adhE and edd.

Application Serial No.: 10/585,040 Inventor(s): MEYNIAL-SALLES et al.

Attorney Docket No.: 2912956-029000

Claim 5. (Currently Amended) The method of claim 1, wherein the initial E. coli strain further

comprises a pyruvate dehydrogenase complex.

Claim 6. (Previously Presented) The method of claim 5, wherein the pyruvate dehydrogenase

complex has low sensitivity to inhibition by NADH.

Claim 7 - 8. (Cancelled)

Claim 9. (Previously Presented) The method of claim 5, wherein the pyruvate dehydrogenase

complex is endogenous.

Claim 10. (Currently Amended) The method of claim 1, wherein one or more heterologous

genes adc, <u>ctfAB</u> etfA and B, and thl are introduced into the evolved <u>E. coli</u> microorganisms to

provide a modified evolved E. coli strain.

Claim 11. (Currently Amended) The method of claim 10, wherein the one or more heterologous

genes adc <u>ctfAB</u> <u>etfA</u> and <u>B</u>, and thl are from C. acetobutylicum.

Claim 12. (Currently Amended) The method of claim 10, wherein the modified evolved *E. coli*

strain comprising one or more heterologous genes adc, ctfAB etfA and B, and thl are grown under

selection pressure in an appropriate growth medium comprising a simple carbon source in order

to cause, in said modified evolved E. coli strain, the evolution of one or more genes involved in

the conversion of acetyl-CoA and acetate to acetone towards an improved acetone synthase

activity, the second generation of resulting evolved microorganisms having an improved 1,2-

propanediol synthase activity and an improved acetone synthase activity are then selected and

isolated.

Claim 13 - 15. (Cancelled)

Application Serial No.: 10/585,040

Inventor(s): MEYNIAL-SALLES et al.

Attorney Docket No.: 2912956-029000

Claim 16. (Currently Amended) An evolved E. coli strain obtained by the method according to

claim 1.

Claim 17. (Currently Amended) The evolved <u>E. coli</u> strain according to Claim 35, wherein the

evolved *E. coli* strain comprises an *lpd* gene encoding a lipoamide dehydrogenase of the

pyruvate dehydrogenase complex, and wherein the *lpd* gene has a point mutation whereby

alanine 55 is replaced by valine.

Claims 18 to 21. (Cancelled)

Claim 22. (Currently Amended) An initial *E. coli* bacterial strain of a microorganism

comprising a deletion of the gene tpiA and a deletion of at least one gene involved in the

conversion of methylglyoxal into lactate.

Claim 23. (Previously Presented) The strain of claim 22, wherein the gene involved in the

conversion of methylglyoxal into lactate is selected among the group consisting of gloA, aldA

and aldB.

Claim 24. (Currently Amended) The strain of claim 22, wherein the initial *E. coli* strain

comprises deletion of the genes gloA, aldA, and aldB.

Claim 25. (Currently Amended) The strain of claim 22, wherein the initial E. coli strain

comprises deletion of the genes *ldhA*, *pflA*, *pflB*, *adhE* and *edd*.

Claim 26. (Currently Amended) The strain of claim 22, wherein the initial *E. coli* strain also

contains a pyruvate dehydrogenase complex.

Claim 27. (Previously Presented) The strain of claim 22, wherein the pyruvate dehydrogenase

complex has low sensitivity to inhibition by NADH.

Application Serial No.: 10/585,040 Inventor(s): MEYNIAL-SALLES et al.

Attorney Docket No.: 2912956-029000

Claims 28 - 31. (Cancelled)

Claim 32. (Currently Amended) The evolved <u>E. coli</u> strain of claim 16, wherein the at least one

gene involved in the conversion of methylglyoxal into lactate is selected from the group

consisting of gloA, aldA and aldB to provide a modified evolved <u>E. coli</u> strain.

Claim 33. (Currently Amended) The evolved <u>E. coli</u> strain of claim 16, comprising deletion of

the genes *gloA*, *aldA*, and *aldB* to provide a modified evolved strain.

Claim 34. (Currently Amended) The evolved E. coli strain of claim 16, further comprising a

modification, the modification comprising deletion of the genes ldhA, pflA, pflB, adhE and edd to

provide a modified evolved strain.

Claim 35. (Currently Amended) The strain of claim 16, wherein the E. coli strain comprises a

pyruvate dehydrogenase complex.

Claim 36. (Previously Presented) The strain of claim 35, wherein the pyruvate dehydrogenase

complex has low sensitivity to inhibition by NADH.

Claim 37 - 38. (Cancelled)

Claim 39. (Previously Presented) The strain of claim 35, wherein the pyruvate dehydrogenase

complex is endogenous.

Claim 40. (Currently Amended) The strain of claim 16, comprising one or more heterologous

adc, <u>ctfAB</u> ctfA and B, and thl.

Claim 41. (Currently Amended) The strain of claim 40, wherein the one or more heterologous

gene or genes adc, <u>ctfAB</u> <u>ctfA and B</u>, and thl are from C. acetobutylicum.

Application Serial No.: 10/585,040 Inventor(s): MEYNIAL-SALLES *et al.*

Attorney Docket No.: 2912956-029000

Claim 42 - 45. (Canceled)

Claim 46. (Currently Amended) An evolved <u>E. coli</u> strain obtained by the method of Claim 10.

Claim 47. (Currently Amended) The evolved *E. coli* strain according to claim 50, wherein the

evolved strain comprises an *lpd* gene encoding a lipoamide dehydrogenase of the pyruvate

dehydrogenase complex, and wherein the *lpd* gene has a point mutation whereby alanine 55 is

replaced by valine.

Claim 48 - 49. (Canceled)

Claim 50. (Currently Amended) The evolved <u>E. coli</u> strain of claim 46, wherein the <u>E. coli</u>

strain comprises a pyruvate dehydrogenase complex.